Data investigation

Rhode Island Medicaid GLP-1 Coverage 2026: PA Pathway, Eligibility & Appeals

Since October 1, 2026, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy or Zepbound prescribed solely for weight loss. Other medically necessary uses need a new PA request; under-21 requests get EPSDT review.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
16 min read·24 citations

Since October 1, 2026, Rhode Island Medicaid no longer covers Foundayo, Saxenda, Wegovy or Zepbound when they are prescribed solely for weight loss. Other medically necessary uses — such as heart-risk reduction, sleep apnea or MASH — need a new prior authorization request with clinical documentation, and requests for members under 21 are reviewed under federal EPSDT rules. GLP-1s for type 2 diabetes remain covered.

Rhode Island Medicaid is administered by the Rhode Island Executive Office of Health and Human Services (EOHHS) through three programs: RIte Care (families and children), Rhody Health Partners (adults), and Integrity for Duals (dual-eligibles). Total Medicaid + CHIP enrollment is approximately 303,351 (September 2025) to 303,480 (October 2025) per healthinsurance.org citing KFF/CMS — representing roughly 28% of the state’s population of ~1.1 million, among the highest Medicaid-share-of-population rates in the United States.

Effective July 1, 2025, Rhode Island consolidated its Medicaid managed care contracts from three MCOs to two: Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC). Tufts Health Plan exited managed Medicaid. Phase II (January 1, 2026) integrated fully dual-eligible beneficiaries into MCO-administered FIDE-SNPs. The state Single PDL — adopted by the EOHHS Pharmacy & Therapeutics Committee — operates as the floor across both MCO formularies.

On January 15, 2026, Governor Daniel McKee submitted his FY2027 Executive Budget. Item 028 (EOHHS Rank #2) proposed ending Rhode Island Medicaid coverage of GLP-1 receptor agonists for chronic weight management. Projected savings: $6.3 million state general revenue, $20.3 million all-funds. Cost driver per the budget: "GLP-1 weight loss costs… roughly quadrupled" between SFY 2024 start and SFY 2025 end in per-member-per-month payments to managed care plans.

The House Finance Committee passed its amended $15.2 billion FY2027 budget on May 29, 2026 (11-2), and the General Assembly adopted the FY2027 budget in June 2026 with the GLP-1 restriction included. On August 5, 2026, EOHHS told providers in a memo titled “GLP-1 State Budget Guidance”: “Pursuant to the Rhode Island State Fiscal Year 2027 Enacted Budget, beginning October 1, 2026, Rhode Island Medicaid will no longer cover certain GLP-1 receptor agonists when they are prescribed solely for weight loss.” The change took effect on that date; the fee-for-service Preferred Drug List updated October 1, 2026 removed the Weight Management Agents class.

One change to know as of November 2026: Novo Nordisk has announced it will discontinue Saxenda, with last wholesaler shipments in late January 2027. If the path your plan uses runs through Saxenda, ask your prescriber and plan how FDA-approved generic liraglutide 3 mg or another drug fits.

Coverage since October 1, 2026

What changed, drug by drug

  • Wegovy, Zepbound, Saxenda, Foundayo — no longer covered when prescribed solely for weight loss. A medically necessary use other than weight loss needs a new PA request with clinical documentation.
  • Members under 21 — every PA request is reviewed for medical necessity under EPSDT requirements.
  • Contrave (naltrexone/bupropion) — not named in the EOHHS memo; we could not confirm its current status. Ask your plan.
  • Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Bydureon BCise — still covered for type 2 diabetes with PA.

Source: EOHHS memo “GLP-1 State Budget Guidance,” August 5, 2026. The memo lists: “Foundayo (Orforglipron) Saxenda (Liraglutide) Wegovy (Semaglutide) Zepbound (Tirzepatide).”

“If continued treatment with one of these medications listed above is medically necessary for an indication other than weight loss, providers must submit a new PA request with the appropriate clinical documentation. For members younger than 21 years of age, all PA requests must be reviewed for medical necessity in accordance with Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) requirements.” — EOHHS, August 5, 2026

Confirm exact PA criteria at the source

The EOHHS memo does not publish clinical criteria for non-weight-loss requests. Check the fee-for-service Preferred Drug List updated October 1, 2026 and your plan’s criteria (NHPRI or UHC). For diabetes, the historical RI Medicaid GLP-1 PA framework requires "history of either metformin or TZD therapy in the past 90 days"; confirm the current wording on the live PDL.

How the FY2027 budget change happened

Governor McKee’s FY2027 Executive Budget Item 028 (EOHHS Rank #2) was introduced January 15, 2026. Key facts from the budget submission, Rhode Island Current, Ocean State Media, and the EOHHS memo:

ElementDetail (verbatim where quoted)
Effective dateOctober 1, 2026. The budget document had allowed “as early as July 1, 2026, but would more likely happen by October 2026 or January 2027” (Rhode Island Current, Jan 27, 2026); the EOHHS memo of August 5, 2026 set October 1, 2026.
State general revenue savings$6.3 million
All-funds savings (federal + state)$20.3 million
Mechanism“Mostly an administrative change to contracts and rates” (EOHHS spokesperson, Ocean State Media). The fee-for-service PDL updated October 1, 2026 removed the Weight Management Agents class.
Cost-growth driverPMPM payments to managed care plans “roughly quadrupled” SFY24 start → SFY25 end. Projected FY27 Q2 growth: “approximately 130 percent (low estimate) and nearly 200 percent (high estimate).”
SFY25 prescription volume24,971 prescriptions for GLP-1s addressing obesity (includes repeat prescriptions). EOHHS told Rhode Island Current it has no count of members who lost coverage.
List-price context“$12,000 annually to roughly $16,000 annually as of March 2025” (WAC for Wegovy / Zepbound at maintenance dose)
ScopeFoundayo, Saxenda, Wegovy and Zepbound “when they are prescribed solely for weight loss” (EOHHS memo). Other medically necessary uses: new PA request. Under 21: EPSDT review. No continuation for existing weight-loss prescriptions is described in the memo.
Legislative pathHouse Finance Committee passed amended FY27 budget May 29, 2026 (11-2) → House and Senate passage → FY2027 budget adopted June 2026 with the GLP-1 restriction → EOHHS provider memo August 5, 2026 → in effect October 1, 2026.

Public discourse on the proposal: the Boston Globe published a commentary on November 3, 2025 opposing the cut — “GLP-1s are a game-changer for R.I.’s obesity crisis. Limiting access to these weight-loss medications is not the answer.” Equity context per Rhode Island Current citing CDC and EOHHS data: 38.5% of Black Rhode Island residents have obesity; 33.9% of Hispanic; 29.5% of white; 44.6% of adults in households earning under $15,000. After adoption, the American Diabetes Association issued a June 25, 2026 statement expressing concern over Rhode Island’s decision.

PA pathway since October 1, 2026

A PA request for Wegovy, Zepbound, Saxenda or Foundayo now has to rest on a medically necessary use other than weight loss, and EOHHS requires a new request with clinical documentation.

Fee-for-service submission

  • EOHHS Pharmacy PA Program (PA forms hub): eohhs.ri.gov/providers-partners/provider-directories/pharmacy/pharmacy-prior-authorization-program. General PA form: eohhs.ri.gov/sites/g/files/xkgbur226/files/2021-03/pa_form_0.pdf
  • PA Call Center fax: 1-401-784-3889
  • Form warning verbatim: “PA FORMS LACKING ALL REQUESTED INFORMATION WILL NOT BE REVIEWED/REQUEST WILL BE DENIED.”

MCO submission

  • NHPRI: nhpri.org/providers/provider-resources/pharmacy/prior-authorization-forms/
  • UHC of New England Community Plan RI PDL (effective April 1, 2026): uhcprovider.com/content/dam/provider/docs/public/commplan/ri/pharmacy/RI-Children-SHCN-RiteCare-RhodyHealth-Preferred-Drug-List.pdf
  • For MCO denials, federal managed-care rules allow 120 calendar days to request a fair hearing after exhausting MCO internal appeal

Standard RI Medicaid PA adjudication timeframes (urgent vs standard) are not specified on the EOHHS pharmacy public pages. Federal Medicaid baseline applies: 24 hours for urgent, 14 days for standard. Any RI-specific override should be confirmed against the live EOHHS provider manual.

What Rhode Island Medicaid actually spends on GLP-1s

Rhode Island reports every Medicaid prescription and dollar it pays for each drug to CMS quarterly. In 2025, Rhode Island Medicaid paid $49M gross for GLP-1 medications across 46,691 prescriptions, with drugs labeled for weight loss (Wegovy, Zepbound, Saxenda) making up 31% of that spending. Figures are before confidential rebates — net cost is substantially lower.

QuarterWegovy rxOzempic rxAll GLP-1 gross
Q1 20251,5165,168$11M
Q2 20251,6995,698$13M
Q3 20251,7875,336$13M
Q4 20251,8975,287$13M
Q1 2026(preliminary)1,8115,147$13M

Source: CMS Medicaid State Drug Utilization Data, fee-for-service and managed care combined; quarters with small cell counts are partially suppressed by CMS, so affected figures are floors. The latest quarter fills in as Rhode Island files late reports. See the national Medicaid GLP-1 spending tracker for every state, or download the full dataset (CSV).

Appeals and fair-hearing pathway

Rhode Island Medicaid fair hearings are governed by 210-RICR-10-05-2 (Appeals Process and Procedures for EOHHS Agencies and Programs). Key verbatim provisions:

  • Filing deadline: “appeals must be filed pursuant to § 2.2.1(A)(4) of this Part within thirty (30) days of the contested agency action. The 30 days begins five (5) days after the mailing date of the notice of an intended agency action.”
  • Expedited review: available “in circumstances when the matter in dispute cannot reasonably be resolved during the standard appeals process without jeopardizing the appellant’s life, health, or ability to obtain the services required to attain, maintain, or regain maximum function.”
  • Continuation of benefits during appeal: requires filing during the “advance notice period” (10 days beginning on the fifth day after the date on the notice of intended action).
  • MCO denials (federal managed-care rules): 120 calendar days to request fair hearing — but MCO internal grievance/appeal must typically be exhausted first.
  • EOHHS Appeals Office: 3 West Road, Cranston, RI 02920. “All emergency expedited hearings will be scheduled and heard telephonically.”
  • HealthSourceRI line: (855) 840-4774. Fax: (401) 223-6317. Online filing via healthyrhode.ri.gov.
  • Forms: “EOHHS Fillable Appeal Form” and “DHS-121NF Request for Hearing”
  • Legal representation: Rhode Island Legal Services, (401) 274-2652 or (800) 662-5034 — free representation for Medicaid appeals.

Primary sources: 210-RICR-10-05-2 · EOHHS Appeals Office · File an Appeal

If you were on a GLP-1 for weight loss: what to do now

Weight-loss-only coverage ended October 1, 2026. Four practical steps:

  1. Ask about a new PA for another qualifying use. If you have established cardiovascular disease, obstructive sleep apnea, MASH, or type 2 diabetes, ask your prescriber whether a new PA request for that indication fits your situation. EOHHS requires a new request with clinical documentation; an approval granted earlier for weight management does not carry over.
  2. Under 21? Ask for an EPSDT medical-necessity review. EOHHS says every PA request for a member younger than 21 must be reviewed for medical necessity under EPSDT requirements. Ask the prescriber to document why the medication is medically necessary for you.
  3. Compare self-pay options with your prescriber. Manufacturer savings cards generally exclude Medicaid members. For self-pay, NovoCare lists the Wegovy pen at $349 per month (with a $199 introductory price on the two lowest doses through December 31, 2026) and the Wegovy pill from $149; LillyDirect lists Zepbound vials from $299 and Foundayo from $149 per month. Do not stop or restart a GLP-1 at a high dose without medical advice. Our cheapest semaglutide providers guide and GLP-1 pricing index compare cash-pay routes side by side, and our list of GLP-1 providers serving Rhode Island narrows them to services available in the state.
  4. Appeal a denial within 30 days. Request expedited review if your health cannot wait. Free representation is available through Rhode Island Legal Services (401-274-2652 or 800-662-5034).

Where Rhode Island fits among state Medicaid programs

Across the state Medicaid programs we’ve reviewed, these coverage-architecture types emerge:

GroupStatesPolicy question
Categorical exclusion + carve-back-in (Wegovy CV / OSA / MASH / pediatric)ME, WV, AR, OK, UT, NE, MSIs there a carve-back-in pathway? Document CV/OSA/MASH indication to ACCESS otherwise-excluded coverage.
Active-coverage stable (no public sunset proposal)CT, NY, WI, MIStandard PA management; coverage in place, no immediate sunset risk.
Weight-loss-only coverage ended; other uses by new PARhode Island (since October 1, 2026)Does a medically necessary use other than weight loss support a new PA request? Under 21: EPSDT review.
Coverage previously droppedCA, NH, PA, SC, MA (Jul 3, 2026), UT (pilot expired Jun 30, 2026), NC (briefly)Coverage eliminated; cash-pay or compounded telehealth only (indication carve-outs vary by state).

Rhode Island now sits close to the categorical-exclusion peer cluster. Where Maine readers ask “can I access GLP-1 coverage by qualifying for the Wegovy CV or Zepbound OSA carve-out?”, Rhode Island readers who lost weight-loss coverage ask “does my documented heart, sleep-apnea, liver or diabetes diagnosis support a new PA request?”

Massachusetts’s MassHealth sunset took effect July 3, 2026, and Utah’s legislative pilot expired June 30, 2026. Rhode Island followed on October 1, 2026 — Rhode Island Current counts it as at least the seventh state in 2026 to end or not renew Medicaid coverage of GLP-1s for obesity, after California, New Hampshire, Pennsylvania, and South Carolina.

Related coverage

  • Hawaii Med-QUEST GLP-1 Coverage — mirror image of RI on political-direction axis: HI currently EXCLUDES Wegovy/Zepbound/Saxenda/Contrave for weight management (AlohaCare verbatim: “Drugs for weight loss, erectile dysfunction, infertility, and cosmetic purposes are not covered”) and SB 3195 (Sen. Kurt Fevella R-Ewa Beach, bipartisan, 2026 Regular Session), which would have scrapped the exclusion, saw no action after its February 2026 committee referral; RI’s Democratic-governor-proposed change ended weight-loss-only coverage on October 1, 2026. HI operates one of the longest-running continuous 1115 demonstrations (since August 1, 1994; extended through Dec 31, 2029).
  • Alaska Medicaid GLP-1 Coverage — opposite coverage posture to RI: AK Medicaid PDL effective March 1, 2026 lists Ozempic / Mounjaro / Rybelsus / Trulicity / Victoza / Bydureon BCISE / Adlyxin as preferred “ON” status but Wegovy / Zepbound / Saxenda do NOT appear in any class of the 42-page PDL (exclusion-by-absence in a Medicaid-expansion state). FFS-only with no MCOs; 231,000+ Medicaid/CHIP enrollees on a single statewide PDL; 229+ federally recognized tribes with Alaska Area IHS + ANTHC operating 8 tribally managed hospitals + 72 tribal health centers + 148 village clinics; 100% FMAP for AI/AN beneficiaries; expansion via Gov. Walker executive action September 1, 2015; PBM Prime Therapeutics Medicaid Administration; single General PA Form for ALL non-preferred drugs; appeals 30 days under 7 AAC 49.030 to Gainwell Fair Hearings
  • Wyoming Medicaid GLP-1 Coverage — inverse coverage trajectory to RI: WY codifies a categorical “Anorexiant products” exclusion in the WDH Pharmacy Services Manual Revision 27 (effective April 15, 2026) page 8 with three FDA-label carve-ins (Wegovy SELECT/CV, Wegovy MASH, Zepbound OSA — the LEAST restrictive OSA carve-in in the categorical cohort, with no CPAP prerequisite); FFS-only with no traditional MCO, WYhealth as Care Management Entity; OptumRx as pharmacy benefit administrator (load-bearing 2026 migration eff. April 15, 2026); smallest US state by population (~580K, ~59,714 enrollment per CMS Oct 2025); non-expansion (2026 expansion defeated 7-23 and 5-26); no AOM legislation 2024-2026; state-employee EGI plan launched GLP-1 weight management via CVS Caremark January 1, 2026
  • Montana Medicaid GLP-1 Coverage — categorical weight-loss exclusion under DPHHS / Mountain-Pacific Quality Health PA after HB 245 made expansion permanent (first state to convert sunsetting expansion to non-sunsetting) and SB 417 (Sen. Ellie Boldman AOM mandate) died 11-1 in committee March 1, 2025; PCCM (Passport to Health) architecture, not capitated MCO
  • North Dakota Medicaid GLP-1 Coverage — middle-ground “covered for everything except obesity”: ND covers Wegovy MACE + Wegovy MASH + Zepbound OSA (one of the most restrictive OSA carve-outs) + Ozempic/Victoza no-PA for antipsychotic-induced weight gain + Imcivree + low-cost AOMs without PA but NOT Wegovy/Zepbound/Saxenda for standalone obesity; HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor 02/12/2025; ND 2025 commercial EHB covers GLP-1s for morbid obesity (inverse of Medicaid)
  • South Dakota Medicaid GLP-1 Coverage — opposite trajectory to RI: SD operates a functional AOM exclusion by ABSENCE (no codified categorical language; the OptumRx SD-specific GLP-1 PA form pre-codes ONLY T2D as the indication checkbox) under FFS-only DSS architecture; ballot-initiative expansion via Amendment D 2022 plus uniquely constitutionalized 90% FMAP trigger on the Nov 3, 2026 ballot via Constitutional Amendment I (HJR 5001 referred House 59-7 / Senate 31-3)
  • Idaho Medicaid GLP-1 Coverage — inverse-trajectory comparison to RI: where RI covered baseline AOM until October 1, 2026, ID excludes baseline AOM through an OPERATIONAL (not statutory) exclusion — IDAPA 16.03.09.662 does NOT enumerate anti-obesity drugs as an excluded class (lower bar to administrative carve-back-in than statutory states); active legislative repeal trajectory (HB 138 defeated 2025, HB 345 signed MCO-by-2030, HB 913 signed April 11, 2026 work-requirements-by-2027) + Office of Group Insurance dropped GLP-1 obesity coverage Nov 1, 2025 create political compounding; PBM Prime Therapeutics; 24-hour PA adjudication; appeals 28 days to neutral / independent OAH
  • Kansas Medicaid GLP-1 Coverage — inverse trajectory: positive-coverage non-expansion state that LOOSENED AOM criteria 2024-2025 by de-listing Wegovy + Zepbound from Table 4 (BMI ≥ 40 severe-obesity gate eliminated) during the same window RI ended weight-loss-only coverage (effective October 1, 2026); the only state in the KFF January 2026 13-state active-coverage cohort whose policy direction was unambiguously LOOSENING
  • Delaware Medicaid GLP-1 Coverage — positive-coverage stable state with unified DMAP PDL across 3 MCOs (Wegovy + Saxenda preferred; Zepbound clinical-exception pathway); §1115 Diamond State Health Plan extended through December 31, 2028; distinct from SEBC state-employee plan $200 copay effective July 1, 2026
  • Vermont Medicaid GLP-1 Coverage — adjacent New England state with the inverse posture: VT excludes baseline AOM but operationalizes three FDA-label carve-outs (Wegovy MACE + Wegovy MASH + Zepbound OSA) under FFS-only Optum-administered pharmacy benefit
  • Maine MaineCare GLP-1 Coverage — categorical exclusion with NO Wegovy MASH carve-out; LD 480 killed March 20, 2025
  • Nebraska Medicaid GLP-1 Coverage — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
  • Utah Medicaid GLP-1 Coverage — weight-loss legislative pilot expired 6/30/2026 without renewal; MACE/OSA/MASH carve-outs continue (strictest OSA criteria: in-lab attended PSG + 70% PAP adherence)
  • West Virginia Medicaid GLP-1 Coverage — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs
  • Mississippi Medicaid GLP-1 Coverage — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages-12+ pathway
  • 50-state Medicaid GLP-1 coverage map — full state-by-state overview
  • GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
  • GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

  1. RI EOHHS memo “GLP-1 State Budget Guidance” (August 5, 2026) — coverage change effective October 1, 2026; lists Foundayo, Saxenda, Wegovy and Zepbound
  2. RI Medicaid Fee-for-Service Preferred Drug List updated October 1, 2026 — Weight Management Agents class removed
  3. RI Medicaid Preferred Drug List effective January 13, 2026 — EOHHS FFS (before the change)
  4. RI EOHHS Pharmacy Program landing
  5. RI EOHHS Pharmacy PA Program (PA forms hub)
  6. 210-RICR-10-05-2 Appeals Process and Procedures — Rhode Island Code of Regulations
  7. Rhode Island Current — McKee’s FY2027 budget drops GLP-1 for weight loss (January 27, 2026)
  8. EOHHS FY2027 Operating Budget Submission, Item 028
  9. Ocean State Media — McKee’s FY2027 budget drops GLP-1 drugs
  10. Becker’s Payer Issues — RI eyes sunset for GLP-1 Medicaid weight-loss coverage
  11. NHPRI Medicaid Weight-Loss PA criteria (Wegovy / Zepbound / Contrave / Saxenda) — effective October 21, 2025
  12. NHPRI Medicaid GLP-1 / GIP-GLP-1 Agonist PA criteria — effective March 17, 2026
  13. UHC Community Plan RI PDL — effective April 1, 2026
  14. Governor McKee FY2027 Budget Press Release
  15. Governor McKee MCO Procurement Announcement (NHPRI + UHC)
  16. KFF — Medicaid Coverage of and Spending on GLP-1s
  17. healthinsurance.org — Rhode Island Medicaid eligibility and enrollment
  18. Boston Globe commentary — GLP-1s game-changer for RI obesity (November 3, 2025)
  19. Stateline — More states consider dropping GLP-1 (April 30, 2026)
  20. American Diabetes Association — press release expressing concern over Rhode Island’s decision (June 25, 2026) — accessed August 25, 2026
  21. Rhode Island Current — These 5 changes for Rhode Island Medicaid take effect Oct. 1 (October 1, 2026)
  22. NovoCare — Wegovy self-pay offer
  23. LillyDirect — Zepbound self-pay · LillyDirect — Foundayo self-pay
  24. Rhode Island Current — The case for maintaining Medicaid coverage for GLP-1s to treat obesity in Rhode Island (June 10, 2026) — accessed August 25, 2026

This article is a primary-source compendium for Rhode Island Medicaid GLP-1 coverage, first published May 2026 and updated October 2026 after the coverage change took effect. It is informational and educational; it is not medical or legal advice. For your individual coverage and PA decisions, consult your prescriber, your Medicaid plan, and the EOHHS Appeals Office.

Further reading

Frequently Asked Questions

No. Since October 1, 2026, Rhode Island Medicaid no longer covers Foundayo (orforglipron), Saxenda (liraglutide), Wegovy (semaglutide) or Zepbound (tirzepatide) when they are prescribed solely for weight loss. The change comes from the FY2027 budget the General Assembly adopted in June 2026; EOHHS announced it to providers in a memo dated August 5, 2026. The drugs are not removed for every use: if one of them is medically necessary for a condition other than weight loss, the prescriber can submit a new prior authorization (PA) request with clinical documentation. For members under 21, every PA request is reviewed for medical necessity under federal EPSDT rules. Contrave (naltrexone/bupropion) is not named in the EOHHS memo, and we have not been able to confirm its current status — ask your plan. GLP-1s prescribed for type 2 diabetes remain covered.
Governor Daniel McKee's FY2027 Executive Budget, introduced January 15, 2026, included Item 028 (EOHHS Rank #2), which proposed striking GLP-1 weight-loss drugs from the Rhode Island Medicaid Preferred Drug List. The budget submission said the change could happen 'as early as July 1, 2026, but would more likely happen by October 2026 or January 2027', and Rhode Island Current reported that 'Coverage of the drugs for weight loss would end on Oct. 1 under McKee's plan.' Projected savings: $6.3 million state general revenue and $20.3 million all-funds (federal + state). EOHHS described it as 'mostly an administrative change to contracts and rates.' The cost driver cited in the budget: GLP-1 weight-loss PMPM payments to managed care plans 'roughly quadrupled' between the start of SFY24 and the end of SFY25. The General Assembly adopted the FY2027 budget with the restriction in June 2026, and it took effect October 1, 2026.
Rhode Island Medicaid paid for 24,971 GLP-1 prescriptions for obesity in State Fiscal Year 2025 (July 1, 2024 — June 30, 2025), per the EOHHS FY2027 budget submission as reported by Rhode Island Current. That count includes repeat prescriptions and brand or dose switches, so it is not a head count. EOHHS told Rhode Island Current in October 2026 that it does not have a count of how many members lost coverage for weight-loss drugs. Equity context per Rhode Island Current citing CDC and EOHHS data: 38.5% of Black Rhode Island residents have obesity; 33.9% of Hispanic residents; 29.5% of white residents; 44.6% of adults in households earning under $15,000. Total Rhode Island Medicaid + CHIP enrollment is approximately 303,351 (September 2025) per healthinsurance.org citing KFF/CMS.
Yes. The House Finance Committee passed its amended $15.2 billion FY2027 budget on May 29, 2026 (11-2), and the General Assembly adopted the FY2027 budget in June 2026 with the GLP-1 restriction included. EOHHS's August 5, 2026 provider memo cites 'the Rhode Island State Fiscal Year 2027 Enacted Budget' as the authority, and the change took effect October 1, 2026. The American Diabetes Association expressed concern in a June 25, 2026 statement. The scope is narrower than a full removal: coverage ended only for Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss; other medically necessary uses go through a new PA request.
Possibly, through a new prior authorization request. The EOHHS memo of August 5, 2026 says: 'If continued treatment with one of these medications listed above is medically necessary for an indication other than weight loss, providers must submit a new PA request with the appropriate clinical documentation.' FDA-labeled uses other than weight loss include Wegovy for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, and Wegovy for MASH with moderate-to-advanced liver fibrosis. The memo does not publish the clinical criteria for those requests, so the documentation your prescriber submits — diagnosis, test results, prior treatments — will decide the outcome. For members under 21, the memo says every PA request is reviewed for medical necessity under EPSDT requirements.
Yes. The October 1, 2026 change applies only to Foundayo, Saxenda, Wegovy and Zepbound prescribed solely for weight loss. Rhode Island Current's October 2026 report confirms the drugs 'will remain covered if prescribed for other conditions like Type 2 diabetes.' Diabetes GLP-1s — Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), Victoza (liraglutide), Rybelsus (oral semaglutide), and Bydureon BCise (exenatide ER) — continue under the existing RI Medicaid diabetes PA criteria. The historical RI Medicaid PA framework requires 'history of either metformin or TZD therapy in the past 90 days' for the GLP-1 receptor agonist class. Confirm current criteria in the EOHHS fee-for-service Preferred Drug List (updated October 1, 2026) and the NHPRI Medicaid GLP-1 Agonists / GIP-GLP-1 Agonists PA criteria (effective March 17, 2026).
Since October 1, 2026, a PA request for these four drugs can be approved only for a medically necessary use other than weight loss, and the EOHHS memo requires a new PA request with clinical documentation — an approval granted earlier for weight management does not carry over. The fee-for-service Preferred Drug List updated October 1, 2026 removed the Weight Management Agents class. Fee-for-service requests go through the EOHHS Pharmacy PA Program (eohhs.ri.gov/providers-partners/provider-directories/pharmacy/pharmacy-prior-authorization-program; PA Call Center fax 1-401-784-3889). The program warns: 'PA FORMS LACKING ALL REQUESTED INFORMATION WILL NOT BE REVIEWED/REQUEST WILL BE DENIED.' Members of Neighborhood Health Plan of Rhode Island (NHPRI) or UnitedHealthcare of New England (UHC) submit through their plan. Contrave is not named in the EOHHS memo; check its status with your plan.
Effective July 1, 2025, Rhode Island consolidated its Medicaid managed care contracts from three MCOs to two: Neighborhood Health Plan of Rhode Island (NHPRI) and UnitedHealthcare of New England (UHC). Tufts Health Plan exited managed Medicaid. Phase II of the procurement (January 1, 2026) moved fully dual-eligible beneficiaries into MCO-administered Fully Integrated Dual Eligible Special Needs Plans (FIDE-SNPs). The state Single PDL — adopted by the EOHHS Pharmacy & Therapeutics Committee — operates as the floor across both MCO formularies; MCOs may add brand-specific preferences but cannot deny coverage of PDL-preferred therapies. RI Medicaid programs by population: RIte Care (families and children); Rhody Health Partners (adults); Integrity for Duals (dual-eligibles). The EOHHS P&T Committee meets in person at the RI EOHHS Virks Building in Cranston (see the EOHHS pharmacy page for the current meeting schedule). Total Medicaid + CHIP enrollment: approximately 303,000 (~28% of Rhode Island's population of ~1.1 million — among the highest Medicaid penetration rates by share of population in the United States).
Rhode Island Medicaid fair hearings are governed by 210-RICR-10-05-2 (Appeals Process and Procedures for EOHHS Agencies and Programs). Verbatim from the regulation: 'appeals must be filed pursuant to § 2.2.1(A)(4) of this Part within thirty (30) days of the contested agency action. The 30 days begins five (5) days after the mailing date of the notice of an intended agency action.' Expedited review is available 'in circumstances when the matter in dispute cannot reasonably be resolved during the standard appeals process without jeopardizing the appellant's life, health, or ability to obtain the services required to attain, maintain, or regain maximum function.' Continuation of benefits during appeal requires filing during the 'advance notice period' (10 days beginning on the fifth day after the date on the notice of intended action). For MCO denials, federal managed-care rules separately allow beneficiaries 120 calendar days to request a fair hearing — but the MCO internal grievance/appeal must typically be exhausted before fair hearing for non-eligibility disputes (PA denials = MCO appeal first). Contacts: EOHHS Appeals Office, 3 West Road, Cranston, RI 02920; HealthSourceRI line (855) 840-4774; fax (401) 223-6317; online filing via healthyrhode.ri.gov. Legal representation: Rhode Island Legal Services (401) 274-2652 or (800) 662-5034. 'All emergency expedited hearings will be scheduled and heard telephonically' per the EOHHS Appeals Office page.
Maine, West Virginia, Arkansas, Oklahoma, Utah, and Nebraska are CATEGORICAL-EXCLUSION states — long-standing AOM exclusions under federal Medicaid §1927(d)(2)(A) where the question is whether a carve-back-in pathway exists for uses such as cardiovascular risk reduction, sleep apnea, or MASH. Rhode Island arrived at a similar place from the other direction: it covered GLP-1s for weight management until October 1, 2026, then ended coverage when they are prescribed solely for weight loss, while leaving other medically necessary uses available through a new PA request. RI's Medicaid GLP-1 weight-loss PMPM roughly quadrupled between SFY24 and SFY25, the same cost pressure that led California, New Hampshire, Pennsylvania, and South Carolina to drop coverage. Rhode Island Current counts Rhode Island as at least the seventh state in 2026 to end or not renew Medicaid coverage of GLP-1s for obesity; Massachusetts's MassHealth change took effect July 3, 2026. Mississippi — the only non-expansion southern positive-coverage state — operates a third model via SPA 23-0013 carve-back-in with an explicit pediatric ages-12+ pathway.
Yes. Rhode Island expanded Medicaid under the Affordable Care Act effective January 1, 2014 — the same effective date as the federal expansion start — extending coverage to adults 19-64 at or below 138% of the federal poverty level. Total Rhode Island Medicaid + CHIP enrollment is approximately 303,351 (September 2025) per healthinsurance.org citing KFF/CMS, representing roughly 28% of Rhode Island's population of approximately 1.1 million — among the highest Medicaid-share-of-population rates in the United States. ACA expansion enrollees specifically: 76,455 as of June 2025. Rhode Island had been one of the states that covered anti-obesity medications under Medicaid; the FY2027 budget change that took effect October 1, 2026 ended that coverage when the drugs are prescribed solely for weight loss.
Manufacturer savings cards generally exclude people with government insurance such as Medicaid, so the realistic paths are self-pay or a new PA for a non-weight-loss indication. Manufacturer self-pay prices: NovoCare lists the Wegovy pen at $349 per month (with a $199 introductory price for the 0.25 mg and 0.5 mg doses, two monthly fills through December 31, 2026) and the Wegovy pill from $149 per month; LillyDirect lists Zepbound single-dose vials from $299 per month and Foundayo from $149 per month. Novo Nordisk's patient assistance program covers Ozempic but not Wegovy, and Lilly Cares does not list Zepbound or Foundayo. If you have established cardiovascular disease, obstructive sleep apnea, or MASH, ask your prescriber whether a new PA request for that indication fits your situation before switching to self-pay. Rhode Island residents who leave Medicaid for employer coverage should check that plan's formulary.
No standalone bill in the Rhode Island General Assembly 2025 or 2026 sessions specifically addressed GLP-1 or AOM Medicaid coverage. The policy lever was the FY2027 Executive Budget itself (Item 028, EOHHS Rank #2), which the General Assembly adopted in June 2026 with the GLP-1 restriction included; it took effect October 1, 2026. The House Finance Committee and Senate Finance Committee were the operative venues. Rhode Island General Assembly tracker: rilegislature.gov. The Boston Globe published a November 3, 2025 commentary opposing the cut, and the American Diabetes Association expressed concern in a June 25, 2026 statement after adoption.
Four practical steps. (1) Ask your prescriber whether you have a qualifying use other than weight loss — such as established cardiovascular disease, obstructive sleep apnea, MASH, or type 2 diabetes. If so, the prescriber can submit a new PA request with clinical documentation, as the EOHHS memo describes. (2) If you are under 21, your PA request must be reviewed for medical necessity under EPSDT rules — ask your prescriber to document why the medication is medically necessary for you. (3) If Medicaid will not pay, compare manufacturer self-pay prices (NovoCare for Wegovy; LillyDirect for Zepbound and Foundayo) with your prescriber, and do not stop or restart a GLP-1 at a high dose without medical advice. (4) If a PA request is denied, file for a fair hearing within 30 days of the notice and request expedited review if your health cannot wait. Rhode Island Legal Services (401-274-2652 or 800-662-5034) provides free representation for Medicaid appeals.
No. Like every other state Medicaid program, Rhode Island Medicaid does not reimburse compounded semaglutide or compounded tirzepatide under any pathway. The PDL covers specific FDA-approved branded products; compounded versions fall outside the FDA-approved labeling that gates PDL coverage. Rhode Island patients who use compounded GLP-1 products pay out-of-pocket through LegitScript-approved telehealth platforms. The October 2024 FDA tirzepatide shortage-resolved declaration and February 2025 semaglutide shortage-resolved declaration mean new compounded prescriptions for these molecules now require documented patient-specific clinical need beyond the previous shortage justification. Since October 1, 2026, Medicaid members who need a GLP-1 for weight loss alone are choosing between compounded options and manufacturer self-pay programs, some of which (the Wegovy pill and Foundayo) start at $149 per month.